United Therapeutics (NASDAQ:UTHR) Director Sells $495,950.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Patusky sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $495.95, for a total transaction of $495,950.00. Following the sale, the director directly owned 1,490 shares of the company’s stock, valued at approximately $738,965.50. This trade represents a 40.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded down $0.30 during trading on Tuesday, reaching $500.00. 483,805 shares of the company traded hands, compared to its average volume of 578,260. The firm has a market capitalization of $21.53 billion, a PE ratio of 18.95, a P/E/G ratio of 4.90 and a beta of 0.86. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $502.77. The company has a 50 day moving average price of $458.75 and a 200-day moving average price of $376.11.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same period last year, the company posted $6.39 earnings per share. The business’s quarterly revenue was up 6.8% on a year-over-year basis. Equities research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC grew its stake in United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the period. Invesco Ltd. raised its stake in shares of United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the period. Darwin Global Management Ltd. purchased a new position in shares of United Therapeutics in the 3rd quarter worth about $317,617,000. Assetmark Inc. grew its position in United Therapeutics by 38.1% during the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after buying an additional 197,384 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in United Therapeutics by 0.7% during the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company’s stock valued at $192,571,000 after buying an additional 4,145 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Cantor Fitzgerald raised their price objective on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday, December 8th. Bank of America lifted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Finally, UBS Group boosted their price target on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.